Premium
Driving Under the Influence of Synthetic Cannabinoid Receptor Agonist XLR ‐11
Author(s) -
Lemos Nikolas P.
Publication year - 2014
Publication title -
journal of forensic sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.715
H-Index - 96
eISSN - 1556-4029
pISSN - 0022-1198
DOI - 10.1111/1556-4029.12550
Subject(s) - synthetic cannabinoids , cannabinoid , agonist , cannabinoid receptor , cannabinoid receptor agonists , rimonabant , inverse agonist , pharmacology , driving under the influence , chemistry , medicine , poison control , receptor , emergency medicine , injury prevention
Abstract The case of a 22‐year‐old male Caucasian driver is presented. He was involved in a traffic collision. At the roadside, he displayed blank stare and mellow speech with a barely audible voice. A DRE found low body temperature, rigid muscle tone, normal pulse, lack of horizontal and vertical gaze nystagmus, nonconvergence of the eyes, dilated pupil size, and normal Pupillary reaction to light. A standard toxicology DUID protocol was performed on the driver's whole blood including ELISA and GC ‐ MS drug screens with negative results. Additional drug screening was undertaken for bath salts and synthetic cannabinoid receptor agonists by LC ‐ MS / MS by a commercial laboratory and identified the synthetic cannabinoid receptor agonist XLR ‐11 in the driver's blood. XLR ‐11 was subsequently quantified at 1.34 ng/mL. This is the first documented case involving a driver operating a motor vehicle under the influence of the synthetic cannabinoid receptor agonist XLR ‐11.